EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

Douglas F Meyer, Hillel Tobias, Albert D Min, Arathi Rajendra, Ivanka Zic, Edward Brettholz, David J Clain, Franklin Klion, David Bernstein, Henry C Bodenheimer

Hepatitis Research and Treatment · 2010

DOI: 10.1155/2010/537827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatitis Research and Treatment, 2010. Verfasst von Douglas F Meyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive Diseases, Beth Israel Medical Center and Albert Einstein, College of Medicine, New York, NY 10003, USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical efficacy with superior invitro antiviral activity, but the maximum tolerated dose is not defined.

Methods

We assessed the efficacy of daily high-dose (24 ug) consensus interferon with weight-based (1000–1200 mg daily) ribavirin in HCV genotype 1-infected non-responder patients.

Results

Six adverse events were documented in five patients, and the trial was terminated with no subject achieving viral clearance.

Conclusions

The occurrence of serious adverse events effectively defined the upper limit of acceptable dose, while also revealing that this dose did not offer enhanced sustained viral clearance.

Autor:innen und Institutionen

  • Division of Digestive Diseases, Beth Israel Medical Center and Albert Einstein, College of Medicine, New York, NY 10003, USA.

Zitieren

APA

Meyer, D. F., Tobias, H., Min, A. D., Rajendra, A., Zic, I., Brettholz, E., Clain, D. J., Klion, F., Bernstein, D., & Bodenheimer, H. C. (2010). Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon. Hepatitis Research and Treatment. https://doi.org/10.1155/2010/537827

Vancouver

Meyer DF, Tobias H, Min AD, Rajendra A, Zic I, Brettholz E, et al. Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon. Hepatitis Research and Treatment. 2010. doi:10.1155/2010/537827

BibTeX
@article{Meyer2010,
  author = {Meyer, Douglas F and Tobias, Hillel and Min, Albert D and Rajendra, Arathi and Zic, Ivanka and Brettholz, Edward and Clain, David J and Klion, Franklin and Bernstein, David and Bodenheimer, Henry C},
  title = {Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon},
  journal = {Hepatitis Research and Treatment},
  year = {2010},
  doi = {10.1155/2010/537827}
}
Kostenlos starten →